» Articles » PMID: 16442673

Plant-made Subunit Vaccine Against Pneumonic and Bubonic Plague is Orally Immunogenic in Mice

Overview
Journal Vaccine
Date 2006 Jan 31
PMID 16442673
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Yersinia pestis, the causative agent of plague, is an extremely virulent bacterium but there are no approved vaccines for protection against it. Our goal was to produce a vaccine that would address: ease of delivery, mucosal efficacy, safety, rapid scalability, and cost. We developed a novel production and delivery system for a plague vaccine of a Y. pestis F1-V antigen fusion protein expressed in tomato. Immunogenicity of the F1-V transgenic tomatoes was confirmed in mice that were primed subcutaneously with bacterially-produced F1-V and boosted orally with transgenic tomato fruit. Expression of the plague antigens in fruit allowed producing an oral vaccine candidate without protein purification and with minimal processing technology.

Citing Articles

Live Plague Vaccine Development: Past, Present, and Future.

Anisimov A, Vagaiskaya A, Trunyakova A, Dentovskaya S Vaccines (Basel). 2025; 13(1).

PMID: 39852845 PMC: 11768842. DOI: 10.3390/vaccines13010066.


Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems.

Bharathi J, Suresh P, Prakash M, Muneer S Heliyon. 2024; 10(18):e37634.

PMID: 39309966 PMC: 11416299. DOI: 10.1016/j.heliyon.2024.e37634.


Immunogenicity and efficacy of recombinant subunit SARS-CoV-2 vaccine candidate in the Syrian hamster model.

Shanmugaraj B, Khorattanakulchai N, Paungpin W, Akkhawattanangkul Y, Manopwisedjaroen S, Thitithanyanont A Biotechnol Rep (Amst). 2022; 37:e00779.

PMID: 36533163 PMC: 9744481. DOI: 10.1016/j.btre.2022.e00779.


Plant Platforms for Efficient Heterologous Protein Production.

Ghag S, Adki V, Ganapathi T, Bapat V Biotechnol Bioprocess Eng. 2021; 26(4):546-567.

PMID: 34393545 PMC: 8346785. DOI: 10.1007/s12257-020-0374-1.


Induction of Immune Response in Animal Model Using Recombinant Anti-NDV Vaccine.

Shahriari A, Bagheri A, Afsharifar A, Habibi-Pirkoohi M Iran J Biotechnol. 2019; 17(1):e2215.

PMID: 31457048 PMC: 6697852. DOI: 10.21859/ijb.2215.